Frankfurt - Delayed Quote EUR

Ascendis Pharma A/S (A71.F)

119.00

-2.00

(-1.65%)

As of 8:01:28 AM GMT+1. Market Open.

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other high growth international stocks to invest in now. What To Expect From The Stock Market in 2025? On January 15, Jurrien […]

Insider Monkey 4 days ago

ASND

ARGX
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P. Morgan Healthcare Conference. “Ascendis is well-positioned for rapid revenue growth with the launch of our first two Endocrinology Rare D

GlobeNewswire 14 days ago

ASND
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available

GlobeNewswire 20 days ago

ASND
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks last month

SAGE

ASND
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) fo

GlobeNewswire last month

ASND
Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

The latest announcement is out from Ascendis Pharma ( (ASND) ). Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization of products using TransCon technology in metabolic and cardiovascular diseases. This agreement grants Novo Nordisk an exclusive license to develop and market products targeting obesity and type 2 diabetes, with Ascendis set to receive a $100 million m

TipRanks last month

ASND
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin - Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children COPENHAGEN, Denmark, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 26 topline results from New InsiGHTS, its P

GlobeNewswire last month

ASND
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

PDUFA goal date is July 27, 2025COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. “This marks another step toward

GlobeNewswire last month

ASND
Exploring Three High Growth Tech Stocks in the United States

The United States market has remained flat over the past week but is up 29% over the past year, with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks involves assessing factors such as innovation, scalability, and financial health to capitalize on future opportunities.

Simply Wall St. last month

ASND

BTDR

PHR
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

The initial exclusive distribution arrangement was announced in January 2024.

Pharmaceutical Technology last month

ASND
Ascendis Pharma Reports Third Quarter 2024 Financial Results

– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025 – SKYTROFA Q3 revenue of €47.2 million – 60%+ year-over-year volume growth offset by current and prior period sales deductions – Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 - €220 million, and fu

GlobeNewswire 2 months ago

ASND
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2024 financial results. Those who would like to participate may access the live webca

GlobeNewswire 2 months ago

ASND
High Growth Tech Stocks In The United States To Watch

The market has been flat over the last week but is up 31% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability while aligning with these positive market trends.

Simply Wall St. 2 months ago

ASND

MIRM

ARQT
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

Pharmaceutical Technology 2 months ago

NVO

GLDAF

ASND
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

The main project is a once-monthly GLP-1 receptor agonist for obesity and type 2 diabetes

GuruFocus.com 2 months ago

NVO

ASND
Ascendis Pharma and Novo Nordisk Join Forces

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and cardiovascular diseases, including a monthly TransCon Semaglutide product for obesity and type 2 diabetes. The agreement could bring Ascendis up to $285 million in milestone payments, along with sales-based royalties. Novo Nordisk will handle the clinical development and commercialization, with Ascendis foc

TipRanks 2 months ago

ASND
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases. The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional p

TipRanks 2 months ago

NONOF

NVO

ASND
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases. Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year The agre

Benzinga 2 months ago

NVO

ASND
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases

Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases

PREMIUM
MT Newswires 2 months ago

NVO

ASND
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

- Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary produc

GlobeNewswire 2 months ago

ASND

Performance Overview

Return	A71.F	MSCI WORLD
YTD	-9.85%	+3.70%
1-Year	-1.65%	+19.91%
3-Year	+17.82%	+29.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ascendis Pharma A/S (A71.F)

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Exploring Three High Growth Tech Stocks in the United States

Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

High Growth Tech Stocks In The United States To Watch

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

Ascendis Pharma and Novo Nordisk Join Forces

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Performance Overview